Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study

Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging rat studies for its lead drug candidate MB-204.

"This rat study, along with the GLP study on dogs, are the last two key studies we need to complete before entering phase 1 human clinical testing of our lead asset - MB-204," said Dr. Mark Williams, Chief Science Officer of Marvel Biosciences. "We are also in the final preparation stage of initiating the 4-week dose-ranging GLP studies on dogs and will update our shareholders on our progress shortly."

"We look forward to completing these two critical studies of MB-204 and entering human trials in the coming months, which is an important value-creating milestone for Marvel and our shareholders," said Rod Matheson, CEO of Marvel Biosciences. "MB-204 to date has shown very promising results, and we believe that this asset has the potential to reduce symptoms of depression and Alzheimer's, both of which are significant and growing problems. We look forward to advancing our lead asset MB-204 through human trials and playing a pivotal role in addressing this growing addressable market."

In the United States, it is estimated that one in ten senior citizens over the age of 65 suffer from dementia. MB-204 is a novel solution to Alzheimer's that has similar properties to the Food and Drug Administration-approved drug, Istradefylline. MB-204 has, through the Company's studies, proven to be more effective and longer lasting than Istradefylline in pre-clinical studies.

MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration.

About Marvel Biosciences Corp.
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations:
Virtus Advisory Group
Tel: 416-644-5081
Email: info@virtusadvisory.com

Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/157765

News Provided by Newsfile via QuoteMedia

MRVL
The Conversation (0)
Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021

Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021

The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience

The SNN Network Canada Virtual Event begins on Tuesday, December 7, 2021 with the "MicroCap Investing Workshop" starting at 8:00am EST and featuring well-known financial influencers, investors, fund managers, and key opinion leaders including: Dave Barr, Sharon Wang, Paul Andreola, Becky Popoff, Harold Leishman, Sean MacGillis, and more!

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021

The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience

The SNN Network Canada Virtual Event begins on Tuesday, December 7, 2021 with the "MicroCap Investing Workshop" starting at 8:00am EST and featuring well-known financial influencers, investors, fund managers, and key opinion leaders including: Dave Barr, Sharon Wang, Paul Andreola, Becky Popoff, Harold Leishman, Sean MacGillis, and more!

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
CSE:NUR

NuRAN Wireless Reports Audited Annual Financial Results

NuRAN Wireless Inc. (“NuRAN Wireless” or the “Company”) (CSE:NUR) (OTC:NRRWF) (FSE:1RN) , a leading supplier of mobile and broadband wireless solutions to connect the next billion, is pleased to announce its audited financial results for the twelve months ended October 31, 2018. All dollar amounts are expressed in Canadian currency.

NuRAN Wireless Inc.-Technology Leadership in the Making

Keep reading...Show less
Carbon Done Right Announces Receipt of Fourth Disbursement of Financing for Sierra Leone Rewilding Project

Carbon Done Right Announces Receipt of Fourth Disbursement of Financing for Sierra Leone Rewilding Project

Carbon Done Right Developments Inc. (CNW Group/KLIMAT X Developments Inc.)

Carbon Done Right Developments Inc. ("Carbon Done Right" or the "Company") (TSXV: KLX) (FSE: Q1C) a leading provider of high-quality carbon credits sourced exclusively from afforestation and reforestation projects developed and owned by the Company and its stakeholders, is pleased to announce the completion of all milestones required for the fourth disbursement under the pre-purchase agreement reached with BP Carbon Trading Ltd announced on the 14 th June, 2023. The next milestone for a further disbursement is due within the next four weeks.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Bitcoin Well Adds Mark Binns as Capital Markets Advisor

Bitcoin Well Adds Mark Binns as Capital Markets Advisor

(TheNewswire)

Bitcoin Well Inc.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Carbon Done Right Announces Brokered Private Placement

Carbon Done Right Announces Brokered Private Placement

/THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

Carbon Done Right Developments Inc. ("Carbon Done Right" or the "Company") (TSXV: KLX) (FSE: Q1C), formally Klimat X Developments Inc., a company that carries on the business of developing validated and verified carbon credits from afforestation and reforestation of degraded land areas and marine ecosystems, including mangroves, for sale into international voluntary carbon markets, is pleased to announce that is has entered into an agreement with Leede Jones Gable Inc. (the " Agent ") to act as sole agent in connection with a commercially reasonable "best efforts" private placement of up to a maximum of 43,111,000 common shares of the Company (the " Common Shares "), at a price of C$0.05 per Common Share (the " Issue Price "), for gross proceeds to the Company of approximately C$2.1 million (the " Offering "), subject to the maximum amount that may be issued under Part 5A (the " Listed Issuer Financing Exemption ") of National Instrument 45-106 Prospectus Exemptions (" NI 45-106 "). The pricing of the Offering is based on a 6.2% discount to the Volume Weighted Average Price over the prior 30 trading days. The company has calculated a six month Volume Weighted Average Price of $0.09 and $0.132 over 12 months.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Bion Announces Voluntary Share Surrender

Bion Announces Voluntary Share Surrender

Bion Environmental Technologies, Inc. (OTC QB: BNET), a leader in advanced livestock waste treatment technology and premium sustainable beef, announced that several of its largest shareholders have agreed to return up to 30 percent of their holdings to the company for cancellation.

Heirs of Dominic Bassani, Bion's former CEO and largest shareholder who passed in November, will return approximately 20 percent before the Company's June 30, 2024, fiscal year end, with another 10 percent upon Bion meeting funding milestones that are consistent with the company's growth objectives. Mark Smith, Bion's current President, who is transitioning to retirement during this year, will return approximately 30 percent of his holdings over the next month.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×